Uniqure NV. Daily Stock Analysis

Daily Stock Analysis, QURE, Uniqure NV, priceseries

Uniqure NV. Daily Stock Analysis
Stock Information
Open
15.58
Close
15.54
High
15.98
Low
15.17
Previous Close
15.78
Daily Price Gain
-0.24
YTD High
21.85
YTD High Date
Jan 3, 2022
YTD Low
15.01
YTD Low Date
Feb 24, 2022
YTD Price Change
-5.96
YTD Gain
-27.72%
52 Week High
38.80
52 Week High Date
Sep 21, 2021
52 Week Low
15.01
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-16.41
52 Week Gain
-51.36%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 1. 2017
5.72
Feb 16. 2017
6.44
11 Trading Days
12.60%
Link
LONG
May 18. 2017
5.16
May 25. 2017
5.45
5 Trading Days
5.58%
Link
LONG
Jun 21. 2017
5.32
Jul 27. 2017
7.74
25 Trading Days
45.57%
Link
LONG
Sep 28. 2017
9.07
Oct 18. 2017
10.67
14 Trading Days
17.64%
Link
LONG
Oct 19. 2017
15.16
Oct 26. 2017
16.07
5 Trading Days
5.97%
Link
LONG
Dec 21. 2017
17.86
Jan 8. 2018
18.80
10 Trading Days
5.28%
Link
LONG
Apr 9. 2018
25.57
Apr 24. 2018
29.16
11 Trading Days
14.04%
Link
LONG
May 22. 2018
32.34
Jun 11. 2018
34.68
13 Trading Days
7.24%
Link
LONG
Jan 24. 2019
31.30
Feb 7. 2019
33.05
10 Trading Days
5.60%
Link
LONG
Feb 15. 2019
37.46
Mar 22. 2019
64.50
24 Trading Days
72.18%
Link
LONG
Jun 12. 2019
69.91
Jun 24. 2019
76.46
8 Trading Days
9.36%
Link
LONG
Oct 24. 2019
46.02
Nov 14. 2019
51.18
15 Trading Days
11.20%
Link
LONG
Dec 10. 2019
64.99
Jan 2. 2020
69.95
15 Trading Days
7.64%
Link
LONG
Apr 6. 2020
47.81
May 8. 2020
60.85
23 Trading Days
27.28%
Link
LONG
Oct 19. 2020
37.54
Oct 28. 2020
39.51
7 Trading Days
5.26%
Link
LONG
Aug 31. 2021
29.00
Sep 23. 2021
35.73
16 Trading Days
23.22%
Link
LONG
Nov 1. 2021
31.70
Nov 10. 2021
33.82
7 Trading Days
6.68%
Link
Company Information
Stock Symbol
QURE
Exchange
NasdaqGS
Company URL
http://www.uniqure.com
Company Phone
1-339-970-7000
CEO
Matt Kapusta
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001590560
About

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, Netherlands.

Description

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading